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T 
he  demonstration  of  autologous  CD8 +  CTL  with 
specificity for class I MHC-restricted tumor antigens 
is a cornerstone of the field of tumor immunology (1,  2). 
Immunotherapy of malignant diseases is therefore an attrac- 
tive  possibility,  but  the  frequency  of immunoreactive  T 
cells  is  extremely low  and  variable in  the  tumor-bearing 
host  (3,  4).  The critical  challenge  now is to  augment the 
frequency of active, tumor-specific lymphocytes, thus trans- 
lating a trace repertoire into effective immune responses in 
vivo. Three papers in this issue have begun to address this 
challenge by using dendritic cells to elicit antigen-specific, 
tumor-resistant immune responses in mice (5-7). 
Approaches  to Active Cell-mediated Immunotherapy 
of Malignant Disease 
Tumor Cells Transduced with Cytokines.  With the advent 
of molecular approaches to alter cell function, investigators 
have  evaluated  the  therapeutic  use  of tumor  cells  trans- 
duced with cytokine genes to enhance  in vivo immunity. 
The  rationale  is  that  cytokine  production  by  the  tumor 
would increase protective local and systemic responses, in- 
cluding the expansion of CTLs, the recruitment of helper 
T  cells  and  NK cells,  and  the  enhancement  of host APC 
function,  while  minimizing  systemic  toxicity  (8,  9).  A 
number of cytokines have exhibited activity in vivo in ro- 
dents, including resistance to subsequent challenges by na- 
tive, nontransduced tumors. Dranoffet al. separately evalu- 
ated eight cytokines, each encoded by a retroviral construct 
and  expressed  in  the  B16-F10  melanoma  cell  line  (10). 
GM-CSF-transduced tumor cell vaccines proved to be the 
most  effective in  eliciting  potent,  durable,  tumor-specific 
immunity, and successful vaccination required both CD4 + 
and CD8 + T  cells.  It was hypothesized that GM-CSF ex- 
pressed by the tumor vaccine might locally recruit and en- 
hance  the activity of host APCs,  like dendritic  cells.  Fur- 
ther studies using parental --4 F 1 bone marrow chimeras in 
fact demonstrated that priming of an antitumoral T  cell re- 
sponse can occur in the context of MHC products on host 
APCs,  rather  than  the  MHC  molecules  expressed by the 
immunizing tumor (11). 
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Enhancing  Costimulatory  Signals  Delivered  by  Tumors. 
Among the many plausible mechanisms by which  tumors 
may escape immune  rejection is their failure  to  exert the 
necessary and sufficient costimulatory signals for stimulating 
resting or unprimed T  cells.  The CD28/CTLA-4/CD80/ 
CD86  family of molecules represents attractive candidates 
to  enhance  immune  responsiveness  against  tumors,  given 
their capacity to enhance cytokine production and prevent 
anergy.  Some murine  tumor models have in fact demon- 
strated that transduction of B7-1/CD80 genes for costimu- 
lation with tumor antigen can elicit a host response against 
a tumor in an antigen-specific fashion (12-15). This has re- 
sulted in actual tumor rejection, as well as antigen-specific 
immunologic memory manifested by resistance to  rechal- 
lenge by nontransduced tumor cells. 
Dendritic  Cells as an Approach to Enhance the Host Response 
to  Tumor  Antigens.  Dendritic  cells  are  bone  marrow- 
derived leukocytes whose properties for antigen presenta- 
tion and initiation of T  cell-dependent immune responses 
are  more  developed  and  far  more  potent  than  those  of 
other antigen-presenting cells (16). Although a trace leuko- 
cyte  population,  dendritic  cells  are  widely  distributed  in 
vivo at portals of entry for efficient antigen capture. They 
can also retain  and present antigen  in  immunogenic form 
for several days (17,  18). Dendritic cells' migratory proper- 
ties via blood and afferent lymph facilitate their movement 
between sites  of origin and antigen  capture to the T  cell- 
enriched  areas  of lymphoid  tissue.  There  they  are  posi- 
tioned  to  sample large numbers of circulating T  cells  and 
select infrequent clones with specific reactivity for the pre- 
sented antigen. This in turn should foster the egress of acti- 
vated, antigen-specific T  lymphocytes into the periphery as 
effectors. 
In addition  to  the  formation of peptide-MHC  ligands 
for clonotypic TCRs, dendritic  cells  express high levels of 
critical accessory signals,  both costimulatory and adhesive, 
including  B7-1/CD80,  B7-2/CD86,  ICAM-1/CD54, 
ICAM-3/CD50,  and  others  (19-22).  This  is pertinent  to 
the murine models cited above, where costimulation with 
tumor antigen has proven critical to tumor immunogenic- 
ity.  This  potent  accessory phenotype is  also  presumed to 
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CTL responses, independent of CD4 + help (23-26). 
Several reports have documented the ability of antigen- 
pulsed dendritic  cells  to prime class II MHC-restricted  T 
cells  in vivo  (17,  27).  By using parental dendritic  cells  to 
immunize F~ hybrids, one of the critical experimental find- 
ings was that priming and immune responsiveness occurred 
only in the context of the shared parental MHC haplotype. 
No reactivity was demonstrated in the context of the un- 
shared  haplotype,  proving that  antigen  was  not just  shed 
from the immunizing dendritic ceils and presented by host 
APCs. 
It has also been shown that murine dendritic cells loaded 
with  peptide  can  prime  antigen-specific  CD8 +  CTLs  in 
vivo (28,  29).  By using as few as 0.5-1  ￿  105  GM-CSF- 
generated,  murine  bone  marrow-derived  dendritic  cells 
pulsed with OVA peptide, Porgador and Gilboa (29)  have 
generated potent,  antigen-specific CTL activity.  Immuni- 
zation with OVA-pulsed dendritic  cells induced CTL that 
lysed not  only targets pulsed with  the  OVA peptide,  but 
also  target ceils expressing OVA peptide after transduction 
with OVA protein. Alternative adjuvants to dendritic cells 
could not prime these antigen-specific CD8 + CTL. 
Investigators in this and other contexts are now applying 
methods  for  generating  large  numbers  of dendritic  cells 
from precursor populations. No longer are investigators de- 
pendent  upon  the  small numbers  of terminally differenti- 
ated dendritic  cells  that can be obtained from most tissues 
like blood.  In both murine and human systems, GM-CSF 
has  proven  to  be  an  essential  cytokine  in  dendritic  cell 
growth and differentiation (30-39), with additional contri- 
butions by TNF-(x or CD40L/gp39  (32-35,  40-42),  IL-4 
(35,  43), and c-kit ligand (41,  42). 
Antigen-pulsed Dendritic Cells Generate Protective Immunity 
to  Tumors.  All of these considerations provide a rationale 
for using dendritic cells as immunogens against malignantly 
transformed cells.  Dendritic  cells  have been implicated in 
the generation of largely class II MHC-restricted  host re- 
sponses to tumors (44-46). The initiation by dendritic cells 
of class  I  MHC-restricted  CD8 +  CTL immunity  against 
tumors, however, has been experimentally tested in murine 
models for the first time in the papers under consideration 
here (5-7). 
Celluzi et al. have used murine dendritic ceils generated 
from bone marrow with the support of GM-CSF and IL-4 
(6).  Small numbers of these dendritic  cells,  pulsed with an 
OVA peptide that constitutes a strong CTL epitope [SIIN- 
FEKL],  protected mice against a lethal  challenge  with  an 
OVA-transduced  tumor  cell  line.  Protection  was  CD8 + 
mediated and OVA specific. These mice survived a second 
challenge,  however,  by  the  more  weakly  immunogenic, 
untransduced,  or  parental  tumor.  These  results  comple- 
ment earlier studies by Boon  and  colleagues using turn  n~g 
variants (1), and they suggest the possibility that immuniza- 
tion  by  dendritic  cells  with  a  potent  antigen,  simulta- 
neously expressed by a poorly immunogenic  tumor,  may 
effect subsequent  resistance  to  the  tumor itself.  In reality, 
the great majority of tumor antigens are either unknown or 
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indeterminate  with  regard  to  their  immunogenic  CTL 
epitopes.  To  counter  this  problem,  Zitvogel  et  al.  have 
used  unfractionated,  acid-eluted peptides from tumor cell 
lines  of three  different  histologies  and  derived  from  two 
mouse strains to load syngeneic dendritic cells for vaccina- 
tion  (5,  47).  This approach may have provided additional 
class II MHC-restricted  epitopes for stimulation of helper 
lymphocytes and enabled the concomitant presentation  of 
several tumor antigens.  Dendritic  cells  were  again  gener- 
ated  from  murine  bone  marrow  under  the  influence  of 
GM-CSF  and  IL-4, and  they were  again  highly effective 
adjuvants  in  small  numbers.  Successful  immunization  by 
these antigen-pulsed dendritic cells was documented by the 
elimination  or suppression  of growth  by small but  estab- 
lished tumors, in contrast to rejection of a tumor challenge 
after vaccination. An important role for costimulatory sig- 
nals  provided by dendritic  cells  was  demonstrated  by the 
partial  inhibition  of their  e~cacy  as  immunogens  when 
mice were systemically treated with CTLA4-Ig. Other ac- 
cessory ligand-receptor interactions  could he  expected  to 
account for the remaining activity. Important contributions 
by cytokines  (e.g.,  IL-12,  TNF-c~,  and  IFN-~/)  to  tumor 
resistance were also identified. 
Paglia  et al.  evaluated  the  generation  of tumor-specific 
CTL and in vivo tumor protection against a [3-galactosidase 
([3-gal)-transduced murine tumor cell line (7). Two exper- 
imental  findings  merit highlight.  The  first is  that  in  vivo 
priming of CTL and protection against a subsequent tumor 
challenge  required  only  small  numbers  of antigen-pulsed 
dendritic  cells.  Standard  microbial adjuvants  proved inac- 
tive, as did unpulsed dendritic  cells  or antigen alone.  The 
second notable finding is that  GM-CSF-generated, bone- 
marrow-derived dendritic  cells were able to process intact 
soluble  [3-gal  protein  for peptide  presentation  via  class  I 
MHC to CD8 + CTL. 
Caveats and Future Directions.  Despite the substantial in- 
terest  in  these  reports,  several precautions  are  warranted. 
First,  these  are all  routine  tumor models.  It has yet to be 
proven that human  dendritic  cells  present  tumor antigens 
and elicit specific T  cell immune responses, even in vitro. 
Next,  significant  helper  responses  are  most  likely  being 
generated in vivo because of the exposure of the dendritic 
cells to FCS during in vitro expansion and differentiation. 
The substitution of FCS-free cultures for human trials may 
require  the  addition  of class  II MHC  helper  epitopes  to 
class  I  MHC  antigen-pulsed  dendritic  cell  inmmnization 
strategies. 
The longevity of the response has also not yet been rig- 
orously tested.  Zitvogel et al.  (5)  did use three to four bi- 
weekly immunizations with peptide-pulsed dendritic  cells, 
but any advantage conferred by booster immunizations on 
the long-term durability of positive responses remains un- 
answered. Also untested is the ability of dendritic  cell im- 
munizations to overcome tumor-specific suppressor popu- 
lations. Early studies in the field of tumor immunology by 
North and colleagues have in fact demonstrated that CD4 + 
lymphocytes can actively suppress protective cell-mediated 
immunity under conditions of high tumor burden (48). Where, then, does one proceed? Implicit in all of the pa- 
pers considered here is the usefulness of methods to gener- 
ate large numbers of dendritic cells, rather than relying on 
the isolation of scarce, terminally differentiated populations 
from  accessible sites  like  human  blood  or  mouse  spleen. 
This  field is moving forward because  of the  definition of 
cytokines that enhance  dendritic cell growth and develop- 
ment from proliferating and nonproliferating precursors in 
both mice and humans.  As noted above, GM-CSF plays a 
pivotal  role,  additionally supported  by  TNF-~x,  CD40L/ 
gp39, IL-4, c-kit ligand, and likely additional cytokines that 
have not yet been identified (32-38, 40-43). 
Among  the  remaining  challenges  will be  how  to  load 
dendritic cells with  the  correct antigens for stimulation of 
antitumoral immunity.  An obvious strategy in addition to 
the  methods  presented in  this issue is the  transduction  of 
genes encoding relevant proteins into dendritic cells as they 
divide from cycling precursors and intermediates. In all of 
these  cases,  dendritic  cells  could  tailor  peptides  to  their 
own MHC  molecules, obviating the need to synthesize tu- 
mor-specific peptides, most of which have stringent MHC 
restrictions. 
It remains unclear, however, whether dendritic cell im- 
munizations  would  induce  immunity  against  established 
disease  in  hosts  with  high  tumor  burdens.  An  objective 
more likely to  succeed would be  to  test dendritic cells as 
adjuvant  therapy for minimal residual disease after defini- 
tive treatment of primary tumors.  Melanoma offers an ob- 
vious starting point, in view of the extent to which tumor 
antigens and lymphocyte reactivity are already defined for 
this malignancy (2). Many of the issues still confronting the 
use of dendritic cells for cancer immunotherapy, however, 
will require carefully planned human trials. 
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